SCHEMBL7120571

SCHEMBL7120571

O=C(Nc1ccc(Br)cc1)c1cc(Br)ccc1NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.65
KMT2A Q03164 7/20 0.65
LMNA P02545 7/20 0.65
MEN1 O00255 6/20 0.65
MAPT P10636 6/20 0.65
SLC10A6 Q3KNW5 2/20 0.65
SLC10A2 Q12908 1/20 0.65
SLC10A1 Q14973 1/20 0.65
HTT P42858 6/20 0.63
RECQL P46063 3/20 0.63
ALDH1A1 P00352 4/20 0.56
POLB P06746 2/20 0.56
MCOLN3 Q8TDD5 1/20 0.49
METAP2 P50579 1/20 0.46
PTPN2 P17706 2/20 0.45
PTPN1 P18031 2/20 0.45
PTPN5 P54829 2/20 0.45
GFER P55789 1/20 0.44
PRSS12 P56730 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7214479 0.96 SLC10A6 (0.72) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL7213170 0.93 MEN1 (0.76) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL7208737 0.86 MEN1 (0.67) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL492639 0.85 SLC10A6 (0.56) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL7213034 0.84 MEN1 (0.57) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL492766 0.82 SLC10A2 (0.52) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL492769 0.82 SLC10A2 (0.52) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL7127128 0.81 SLC10A2 (0.60) KMT2ALMNAMEN1MAPTSLC10A6
SCHEMBL27561779 0.80 SLC10A6 (0.50) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL7116008 0.80 SLC10A6 (0.85) KMT2ALMNAMEN1MAPTSLC10A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US claimed
CN-1429108-A Phosphate transport inhibitors SMITHKLINE BEECHAM CORP (US) 2003-07-09 CN claimed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP claimed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO claimed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO claimed
US-20030216449-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-20 US disclosed
US-20030212074-A1 Phosphate transport inhibitors SMITHKLINE BEECHAM CORPORATION 2003-11-13 US disclosed
CN-1429108-A Phosphate transport inhibitors SMITHKLINE BEECHAM CORP (US) 2003-07-09 CN disclosed
EP-1202729-A1 PHOSPHATE TRANSPORT INHIBITORS SmithKline Beecham Corporation (US) 2002-05-08 EP disclosed
WO-2002028353-A2 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-11 WO disclosed
WO-2001087294-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-22 WO disclosed
WO-2001082924-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-08 WO disclosed
WO-2001005398-A1 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216449-A1 Phosphate transport inhibitors SLC34A2, SLC34A1, SLC34A3 SMN1; SMN2 4142/4885KMT2A 4033/4885LMNA 4639/4885
US-20030212074-A1 Phosphate transport inhibitors SLC34A2, SLC34A3, SLC34A1 SMN1; SMN2 4632/4885KMT2A 3005/4885LMNA 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.